 Transitions to clinical trials are vital in order to make further strides (5) Objectives:
In 2010, the Center for Disease Control and Prevention reported that nearly 2.5 million traumatic brain injuries occurred either in isolation or in conjunction with another injury.
The results and long-term effects of such injuries span a multitude of outcomes, with research acknowledging the increased likelihood of seizures following TBI. Additionally, there is an increased potential for the development of epilepsy, also referred to as posttraumatic epilepsy (PTE).
PTE is defined as two or more seizures, thought to be related to the injury itself, that follow a traumatic injury occurring later than one week following the injury.
Patients with TBI are at higher risk for the development of epilepsy relative to the general population. PTE is a significant and debilitating issue that complicates recovery after brain injury.
Age, previous seizures, smoking, genetics, timing of seizures and types of injury, all play a role in the potential for the development of PTE. Furthermore, these factors create a wide range of outcomes which further complicate risks and treatment.
With risk identification, clinicians and researchers alike may be able to more effectively identify treatment and rehabilitation options. As more research is conducted, a greater understanding of new technology and potential for the improvement of treatment is established.
In developing and perfecting these treatments, hopefully a more widespread understanding and protocol may be instituted for individuals at high risk for the development of PTE.  Less than a week after injury  Research has found a link to late seizures (6, 8, 9)  Risk factors for early onset seizures comprise: acute intracerebral hematoma, acute subdural hematoma, younger age, increased injury severity, and chronic alcoholism (1)  More than a week-highest indicator Stepwise process that begins with:
 Anti-Epileptic Drugs (ineffective for late onset) (3, 5, 6, 8) Often followed by (if resistant to drug treatment):
 Resection surgery of the anterior temporal lobe on the non-dominant side (5)  Deep Brain Stimulation (5)  Vagus Nerve Stimulation (17)  Hypothermia Therapy (16) Potential Indicators:
 mossy fiber sprouting (12) (13) (14)  increased electroencephalogram activity (6)  damage to the hippocampus or cortex (7, 12)  neuronal cell loss (12)  blood brain barrier disruption (8, 15)  inflammation (14) 
